mGluR5, CB1 and neuroprotection

被引：3

作者：

Carvalho, Toniana G. ^{[1
]}

Doria, Juliana G. ^{[1
]}

Ribeiro, Fabiola M. ^{[1
]}

机构：

[1] Univ Fed Minas Gerais, Dept Biochem & Immunol, Inst Biol Sci, Belo Horizonte, MG, Brazil

来源：

ONCOTARGET | 2017年 / 8卷 / 03期

关键词：

mGluR5; CB1; neuroprotection; AKT; ERK1/2; Neuroscience; HUNTINGTONS-DISEASE; MOUSE MODEL;

D O I：

10.18632/oncotarget.14086

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3768 / 3769

页数：2

共 7 条

[1] Orchestrated activation of mGluR5 and CB1 promotes neuroprotection [J].

Batista, Edleusa M. L. ;

Doria, Juliana G. ;

Ferreira-Vieira, Talita H. ;

Alves-Silva, Juliana ;

Ferguson, Stephen S. G. ;

Moreira, Fabricio A. ;

Ribeiro, Fabiola M. .

MOLECULAR BRAIN, 2016, 9

[2] The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease [J].

Doria, J. G. ;

de Souza, J. M. ;

Andrade, J. N. ;

Rodrigues, H. A. ;

Guimaraes, I. M. ;

Carvalho, T. G. ;

Guatimosim, C. ;

Dobransky, T. ;

Ribeiro, F. M. .

NEUROBIOLOGY OF DISEASE, 2015, 73 :163-173

[3] Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease [J].

Doria, J. G. ;

Silva, F. R. ;

de Souza, J. M. ;

Vieira, L. B. ;

Carvalho, T. G. ;

Reis, H. J. ;

Pereira, G. S. ;

Dobransky, T. ;

Ribeiro, F. M. .

BRITISH JOURNAL OF PHARMACOLOGY, 2013, 169 (04) :909-921

[4] CB1 cannabinoid receptors and on-demand defense against excitotoxicity [J].

Marsicano, G ;

Goodenough, S ;

Monory, K ;

Hermann, H ;

Eder, M ;

Cannich, A ;

Azad, SC ;

Cascio, MG ;

Gutiérrez, SO ;

van der Stelt, M ;

López-Rodríguez, ML ;

Casanova, E ;

Schütz, G ;

Zieglgänsberger, W ;

Di Marzo, V ;

Behl, C ;

Lutz, B .

SCIENCE, 2003, 302 (5642) :84-88

[5] More surprises lying ahead. The endocannabinoids keep us guessing [J].

Piomelli, Daniele .

NEUROPHARMACOLOGY, 2014, 76 :228-234

[6] Endocannabinoid system as a regulator of tumor cell malignancy - biological pathways and clinical significance [J].

Pyszniak, Maria ;

Tabarkiewicz, Jacek ;

Luszczki, Jarogniew J. .

ONCOTARGETS AND THERAPY, 2016, 9 :4323-4336

[7]

Ribeiro F.M., 2016, PHARM RES, V115, P179

← 1 →